Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein - Report - MDSpire

Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein

  • By

  • Chiao-Chieh Wu

  • Chia-Ling Chen

  • Chen-Yi Chiang

  • Ling-Ling Tu

  • Shih-Jen Liu

  • Chih-Hsiang Leng

  • Hisn-Wei Chen

  • May 22, 2026

  • 0 min

Share

Clinical Report: Improving the Effectiveness of Cancer Vaccines through Electrostatic Modification of an FcγR-Targeting Protein

Overview

This study presents rF9R, a novel vaccine delivery system. The engineered protein improves antigen delivery and CD8+ T-cell activation in tumor models.

Background

Cancer vaccines are a promising form of immunotherapy aimed at activating the immune system to eliminate tumor cells. Despite advancements, challenges such as weak immunogenicity of tumor antigens and suboptimal vaccine delivery persist.

Data Highlights

The rF9R protein demonstrated significant binding with peptides and antigens.

Key Findings

  • The rF9R protein binds peptides and antigens to form stable complexes.
  • In vivo studies showed robust CD8+ T-cell responses with the rF9R/rE7m complex.
  • Combination of rF9R with CpG oligodeoxynucleotides further enhanced immune activation.

Clinical Implications

The rF9R platform may facilitate the development of more effective cancer vaccines by improving antigen delivery and immune response. This approach could streamline vaccine formulation and enhance safety in clinical applications.

Conclusion

The rF9R platform shows promise as a novel strategy for advancing cancer immunotherapy through improved vaccine delivery and immune activation.

Related Resources & Content

  1. The ASCO Post, 2014 -- Vaccine Targeting Tumor Antigen to Dendritic Cell Receptors Induces Antigen-Specific Immunity
  2. The ASCO Post, 2016 -- Breast Cancer Vaccines Moving Forward at a Fast Clip
  3. The ASCO Post, 2014 -- Potential for Therapeutic Autovaccination Against Solid Tumors With Intratumoral Poly-ICLC
  4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma | Journal for ImmunoTherapy of Cancer
  5. Blood Cancer Journal — Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model
  6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma | Journal for ImmunoTherapy of Cancer
  7. Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma | JCO Oncology Advances
  8. Advances in Neoantigen-Based Cancer Vaccines - PMC

Original Source(s)

Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein

  • by Chiao-Chieh Wu, Chia-Ling Chen, Chen-Yi Chiang, Ling-Ling Tu, Shih-Jen Liu, Chih-Hsiang Leng, Hisn-Wei Chen

  • May 22, 2026

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

FOXA2 in cancer: from fundamental biology to clinical translation

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation